Dr. Noah Merrill Merin, MD

Dr. Merin practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Merin's NPI, 1659547487, was assigned on May 1, 2008. Dr. Merin graduated from UC Davis School of Medicine in 2008. Dr. Merin holds California license A110852.

Dr. Merin's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Merin's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Cedars-Sinai Medical Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Merin practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Merin's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Merin is licensed in California.

Dmand AI lists chronic anemia, chronic leukemia, immune deficiency disease, lymphoma and multiple myeloma among the conditions Dr. Merin treats.

CMS data shows 768 Medicare services from Dr. Merin across 8 procedure codes in 2024, for 153 Medicare patients. Medicare paid $71,984 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 153 Medicare patients who saw Dr. Merin in 2024. The largest group is 65 to 74, with 81 patients. 75% of them have high blood pressure, and 70% have high cholesterol. 37% are also on Medicaid. Their average risk score is 3.75, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Merin's median patient age at 65, with 45% women.

In 2024, Dr. Merin wrote 445 Medicare Part D claims for 57 patients. 60% of them were for generic drugs. CMS names the drug for 260 of them, across 11 drugs with 11 or more claims each, at $1,753,464 in total drug cost. In 2023, CMS named 398 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Merin for performance year 2024, reported as part of a group. Dr. Merin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Merin as offering telehealth.

Dmand AI links 9 papers to Dr. Merin, published from 2006 to 2021. 2020 was the busiest year, with 3. The most frequent topics are Fixation, Ocular, Affect and Autistic Disorder. Dr. Merin's most frequent co-authors are Oral Alpan, MD, Michael E. Kleinberg, MD and Bruce T. Liang, MD.

Dmand AI links Dr. Merin to 6 clinical trials, 2 of them phase 1 studies. 2 are still active or recruiting. Conditions studied include Burkitt Lymphoma, COVID-19 and Hematologic Neoplasms. Cedars-Sinai Medical Center sponsors the most, 2.

CMS Open Payments shows 276 general payments to Dr. Merin from 37 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 67% of the total. Genentech, Inc. paid the most, $24,490.

Dr. Merin graduated from UC Davis School of Medicine in 2008.

Dr. Merin is in network with 12 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.